Quoin Pharmaceuticals (NASDAQ:QNRX) Issues Quarterly Earnings Results

Quoin Pharmaceuticals (NASDAQ:QNRX) released its quarterly earnings data on Thursday. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.15, Zacks reports.

Quoin Pharmaceuticals Trading Down 0.5 %

Shares of NASDAQ:QNRX opened at $0.30 on Thursday. The company has a market capitalization of $1.50 million, a PE ratio of -0.07 and a beta of 1.82. Quoin Pharmaceuticals has a 12-month low of $0.27 and a 12-month high of $1.57. The business has a 50 day moving average of $0.41 and a two-hundred day moving average of $0.56.

Insider Activity

In other Quoin Pharmaceuticals news, Director Anthony James Culverwell purchased 100,000 shares of the stock in a transaction on Monday, December 23rd. The shares were bought at an average price of $0.45 per share, for a total transaction of $45,000.00. Following the completion of the transaction, the director now owns 100,317 shares of the company’s stock, valued at $45,142.65. This trade represents a 31,545.74 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Gordon Dunn bought 122,221 shares of Quoin Pharmaceuticals stock in a transaction dated Monday, December 23rd. The shares were acquired at an average cost of $0.45 per share, with a total value of $54,999.45. Following the completion of the purchase, the chief financial officer now owns 151,077 shares in the company, valued at approximately $67,984.65. This trade represents a 423.55 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 777,777 shares of company stock valued at $350,000 in the last three months. 3.70% of the stock is currently owned by corporate insiders.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.